Sugi Predict

Sugi Predict / Compounds / SCHEMBL4136017

SCHEMBL4136017

SCHEMBL4136017

O=C(O)CN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1

nearest known ligand 0.91

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A9 P48067 2/20 0.91
▸ CACNA2D1 P54289 6/20 0.73
▸ CACNB1 Q02641 6/20 0.73
▸ CACNA1B Q00975 5/20 0.73
▸ CACNA1C Q13936 5/20 0.73
▸ HRH1 P35367 4/20 0.67
▸ DRD3 P35462 3/20 0.67
▸ KCNH2 Q12809 3/20 0.67
▸ SLC6A2 P23975 2/20 0.67
▸ SLC6A4 P31645 2/20 0.67
▸ SLC6A3 Q01959 2/20 0.67
▸ HRH2 P25021 2/20 0.67
▸ HTR2A P28223 2/20 0.67
▸ HTR2B P41595 2/20 0.67
▸ USP2 O75604 2/20 0.67
▸ TEK Q02763 1/20 0.67
▸ TDP1 Q9NUW8 1/20 0.67
▸ CACNA1G O43497 1/20 0.64
▸ CACNA1A O00555 1/20 0.62
▸ CHRM2 P08172 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28935916 1.00 SLC6A9 (0.91) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C
Hydrochloric Acid SCHEMBL4140455 0.99 SLC6A9 (0.89) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C
SCHEMBL4139616 0.96 SLC6A9 (1.00) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C
Hydrochloric Acid SCHEMBL4150496 0.94 SLC6A9 (0.97) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C
SCHEMBL1691475 0.91 SLC6A9 (0.74) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C
SCHEMBL10929636 0.89 SLC6A9 (0.72) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C
SCHEMBL4144090 0.89 SLC6A9 (0.72) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C
SCHEMBL27520894 0.86 HRH1 (0.72) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C
SCHEMBL4139140 0.86 SLC6A9 (0.68) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C
SCHEMBL4139144 0.86 SLC6A9 (0.68) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735383-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2014-05-27 — — US claimed
EP-2041088-B1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC (US) 2014-01-08 — — EP claimed
EP-2565183-A1 Glycine transporter-1 inhibitors Amgen Inc. (US) 2013-03-06 — — EP claimed
CN-101479243-B Glycine transporter-1 inhibitors AMGEN INC 2013-01-02 — — CN claimed
US-20120195985-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2012-08-02 — — US claimed
US-20090227595-A1 GLYCINE TRANSPORTER-1 INHIBITORS HITCHCOCK STEPHEN 2009-09-10 — — US claimed
CN-101479243-A Glycine transporter-1 inhibitors AMGEN INC (US) 2009-07-08 — — CN claimed
US-7538114-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2009-05-26 — — US claimed
EP-2041088-A1 GLYCINE TRANSPORTER-1 INHIBITORS Amgen Inc. (US) 2009-04-01 — — EP claimed
WO-2008002583-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2008-01-03 — — WO claimed
US-20080004289-A1 Glycine transporter-1 inhibitors AMGEN INC. 2008-01-03 — — US claimed
CN-121574083-A Substituted 2- (piperazine-1-yl) acetamide derivative, and preparation method and application thereof 中国医学科学院医药生物技术研究所 2026-02-27 — — CN disclosed
US-20260027107-A1 COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA DISC MEDICINE INC (US) 2026-01-29 — — US disclosed
US-20250302823-A1 COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS DISC MEDICINE, INC. 2025-10-02 — — US disclosed
US-20250248995-A1 COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA DISC MEDICINE, INC. 2025-08-07 — — US disclosed
EP-2041088-A1 GLYCINE TRANSPORTER-1 INHIBITORS Amgen Inc. (US) 2009-04-01 — — EP disclosed
WO-2008002583-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2008-01-03 — — WO disclosed
US-20080004289-A1 Glycine transporter-1 inhibitors AMGEN INC. 2008-01-03 — — US disclosed
US-20080004289-A1 Glycine transporter-1 inhibitors AMGEN INC. 2008-01-03 — — US disclosed
US-20080004289-A1 Glycine transporter-1 inhibitors AMGEN INC. 2008-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227595-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC7A11, SLC6A5 SLC6A9 8/4885CACNA2D1 3216/4885CACNB1 2118/4885
US-20250302823-A1 COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS SLC10A1, GFPT1, GLS2 SLC6A9 8/4885CACNA2D1 3432/4885CACNB1 2624/4885
US-20120195985-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC6A5, SLC1A2 SLC6A9 6/4885CACNA2D1 3030/4885CACNB1 1621/4885
US-20250248995-A1 COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA SLC16A1, SLC7A1, SLC6A9 SLC6A9 3/4885CACNA2D1 2487/4885CACNB1 1192/4885
US-20080004289-A1 Glycine transporter-1 inhibitors SLC18A2, SLC7A11, SLC6A5 SLC6A9 8/4885CACNA2D1 3216/4885CACNB1 2118/4885
US-20260027107-A1 COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA SLC6A9, SLC16A1, SLC5A1 SLC6A9 1/4885CACNA2D1 1021/4885CACNB1 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.